PMV Pharma ended the first quarter with $213.1 million in cash, cash equivalents, and marketable securities, compared to $228.6 million as of December 31, 2023. Net cash used in operations was $16.2 million for the three months ended March 31, 2024, compared to $15.0 million for the three months ended March 31, 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMVP:
- PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
- PMV Pharmaceuticals initiated with a Buy at Jefferies
- PMV Pharmaceuticals announces first patient dosed in Phase 2 PYNNACLE trial
- PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
- PMV Pharmaceuticals reports promising efficacy of rezatapopt in OC study